Effects of IL-1β and IL-6 on tissue-type plasminogen activator expression in vascular endothelial cells

Thrombosis Research

Volumn 123, Issue 2, 2008, Pages 342-351

  Larsson, Pia ^a   Ulfhammer, Erik ^a   Karlsson, Lena ^a   Bokarewa, Maria ^b   Wåhlander, Karin ^a,c   Jern, Sverker ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Fibrinolysis; Inflammation; Interleukin 1 ; Interleukin 6; NF B; t PA

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 6; TISSUE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN;

ARTICLE; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOLYSIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; CELL CULTURE; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; TIME;

CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; UMBILICAL VEINS;

EID: 55649100743     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.03.013     Document Type: Article

References (32)

1. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 131 (2005) 417-430
2. Nachman R.L., Hajjar K.A., Silverstein R.L., and Dinarello C.A. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 163 (1986) 1595-1600
3. Emeis J.J., and Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 163 (1986) 1260-1266
4. Schleef R.R., Bevilacqua M.P., Sawdey M., Gimbrone Jr. M.A., and Loskutoff D.J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 263 (1988) 5797-5803
5. Bevilacqua M.P., Schleef R.R., Gimbrone Jr. M.A., and Loskutoff D.J. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 78 (1986) 587-591
6. Hrafnkelsdottir T., Gudnason T., Wall U., Jern C., and Jern S. Regulation of local availability of active tissue-type plasminogen activator in vivo in man. J Thromb Haemost 2 (2004) 1960-1968
7. Kathiresan S., Yang Q., Larson M.G., Camargo A.L., Tofler G.H., Hirschhorn J.N., et al. Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 26 (2006) 1405-1412
8. Ulfhammer E., Larsson P., Karlsson L., Hrafnkelsdottir T., Bokarewa M., Tarkowski A., et al. TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent. J Thromb Haemost 4 (2006) 1781-1789
9. Grames M., Breviario F., Pintucci G., Millet I., Dejana E., van Damme J., et al. Enhancement by interleukin-1 (IL-1) of plasminogen activator inhibitor (PA-I) activity in cultured human endothelial cells. Biochem Biophys Res Commun 139 (1986) 720-727
10. Kawai Y., Matsumoto Y., Watanabe K., Yamamoto H., Satoh K., Murata M., et al. Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells. Blood 87 (1996) 2314-2321
11. Yong K., Cohen H., Khwaja A., Jones H.M., and Linch D.C. Lack of effect of granulocyte-macrophage and granulocyte colony-stimulating factors on cultured human endothelial cells. Blood 77 (1991) 1675-1680
12. Arnman V., Stemme S., Rymo L., and Risberg B. Interferon-gamma modulates the fibrinolytic response in cultured human endothelial cells. Thromb Res 77 (1995) 431-440
13. Jaffe E.A., Nachman R.L., Becker C.G., and Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52 (1973) 2745-2756
14. Muldowney III J.A., Painter C.A., Sanders-Bush E., Brown N.J., and Vaughan D.E. Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thromb Haemost 97 (2007) 263-271
15. Lux W., Klobeck H.G., Daniel P.B., Costa M., Medcalf R.L., and Schleuning W.D. In vivo and in vitro analysis of the human tissue-type plasminogen activator gene promoter in neuroblastomal cell lines: evidence for a functional upstream kappaB element. J Thromb Haemost 3 (2005) 1009-1017
16. Pober J.S. Endothelial activation: intracellular signaling pathways. Arthritis Res 4 Suppl 3 (2002) S109-S116
17. Helle M., Boeije L., and Aarden L.A. Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 18 (1988) 1535-1540
18. Anderson H.D., Rahmutula D., and Gardner D.G. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem 279 (2004) 963-969
19. Arts J., Herr I., Lansink M., Angel P., and Kooistra T. Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Nucleic Acids Res 25 (1997) 311-317
20. Orbe J., Chorda C., Montes R., and Paramo J.A. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha. Haematologica 84 (1999) 306-311
21. Singh U., Devaraj S., and Jialal I. C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 25 (2005) 2216-2221
22. Zhao B., Stavchansky S.A., Bowden R.A., and Bowman P.D. Effect of interleukin-1beta and tumor necrosis factor-alpha on gene expression in human endothelial cells. Am J Physiol Cell Physiol 284 (2003) C1577-C1583
23. Wang D., and Baldwin Jr. A.S. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J Biol Chem 273 (1998) 29411-29416
24. Sohn R.H., Deming C.B., Johns D.C., Champion H.C., Bian C., Gardner K., et al. Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B. Blood 105 (2005) 3910-3917
25. May M.J., and Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. Semin Cancer Biol 8 (1997) 63-73
26. Kumar A., Lin Z., SenBanerjee S., and Jain M.K. Tumor necrosis factor alpha-mediated reduction of KLF2 is due to inhibition of MEF2 by NF-kappaB and histone deacetylases. Mol Cell Biol 25 (2005) 5893-5903
27. Saura M., Zaragoza C., Bao C., Herranz B., Rodriguez-Puyol M., and Lowenstein C.J. Stat3 mediates interleukin-6 inhibition of human endothelial nitric-oxide synthase expression. J Biol Chem 281 (2006) 30057-30062
28. Watson C., Whittaker S., Smith N., Vora A.J., Dumonde D.C., and Brown K.A. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes. Clin Exp Immunol 105 (1996) 112-119
29. Wung B.S., Ni C.W., and Wang D.L. ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells. J Biomed Sci 12 (2005) 91-101
30. Modur V., Li Y., Zimmerman G.A., Prescott S.M., and McIntyre T.M. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J Clin Invest 100 (1997) 2752-2756
31. Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6 (1997) 315-325
32. De Benedetti F., Massa M., Pignatti P., Albani S., Novick D., and Martini A. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 93 (1994) 2114-2119